Sacubitril/valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide? Author's reply

Kardiol Pol. 2021 Jan 25;79(1):105. doi: 10.33963/KP.15745. Epub 2021 Jan 11.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aminobutyrates* / therapeutic use
  • Biphenyl Compounds
  • Drug Combinations
  • Heart Failure* / drug therapy
  • Humans
  • Stroke Volume
  • Tetrazoles / therapeutic use
  • Valsartan

Substances

  • Aminobutyrates
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • Valsartan
  • sacubitril and valsartan sodium hydrate drug combination